Kefauver–Harris Amendment
Kefauver–Harris Amendment
The Kefauver–Harris Amendment or Drug Efficacy Amendment is a 1962 amendment to the Federal Food, Drug, and Cosmetic Act. It was signed into law by President John F. Kennedy on October 10, 1962. The amendment was a response to the Thalidomide tragedy, in which thousands of babies worldwide were born with birth defects as a result of the drug being marketed without proper testing for safety and efficacy.
Background[edit]
The Kefauver–Harris Amendment was introduced by Senator Estes Kefauver and Representative Oren Harris, following the thalidomide tragedy that occurred in Europe in the late 1950s and early 1960s. Thalidomide was a drug marketed as a safe, over-the-counter sedative, but it was later found to cause severe birth defects when taken during pregnancy.
Provisions[edit]
The amendment introduced a series of significant changes to the Federal Food, Drug, and Cosmetic Act. It required drug manufacturers to provide proof of the effectiveness and safety of their drugs before approval, established good manufacturing practices, and mandated the reporting of adverse side effects.
Safety and Efficacy[edit]
The amendment requires that all new drugs must be proven safe and effective for their intended use before they can be marketed. This was a significant change from the previous law, which only required proof of safety.
Good Manufacturing Practices[edit]
The amendment also established standards for good manufacturing practices to ensure that drugs are produced consistently and meet quality standards.
Adverse Event Reporting[edit]
The amendment requires that manufacturers monitor and report any adverse events associated with the use of their drugs.
Impact[edit]
The Kefauver–Harris Amendment has had a significant impact on the drug approval process in the United States. It has led to increased safety and efficacy standards, and has helped to prevent the marketing of unsafe or ineffective drugs.
See also[edit]
References[edit]
External links[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
